Micro Diagnostic Chains
Market Cap
₹489 ₹489 Cr.
P/E
18.06
PEG = P/E ÷ 5yr Forward EPS CAGR

The forward EPS CAGR is estimated individually for each company - factoring in its guidance, industry, and growth drivers - not generic rule-based projection.

Key Ratios

Debt to Equity
Debt to Equity
0.39
Div Yield (%)
Div Yield (%)
-
Individual < 2 lac
Individual < 2 lac
9.45 %
Institutions
Institutions
5.10 %
Market cap
Market cap
489 Cr
No. of Shareholders
No. of Shareholders
1,591
OPM (%)
OPM (%)
19.95 %
PE
PE
18.06
Prom Holding
Prom Holding
49.61 %
ROCE (%)
ROCE (%)
23.83
ROE (%)
ROE (%)
18.08
Sales
Sales
289 Cr
  • Chandan Healthcare
  • Pramodini Medicare
  • Nephro Care India
Last updated on 18 Aug 2026
  • Chandan Healthcare runs pathology-led diagnostics (74% pathology) via owned centres, labs and franchises; legacy pharmacy being divested.
  • Diagnostics carries earnings at 36.6% margin, well above consolidated with pharmacy still included; B2B up 94%, B2C and government also up.
  • Per management, integrated owned-centre, lab, franchise and institutional network under one-district-one-lab; prioritises B2C/B2B, caps government below 40%.
  • Building 8 comprehensive centres, labs, PET and genome capacity toward franchise-led diagnostics; extra capex mainly internal accruals.
  • Execution hinges on converting additions into revenue; raised >50% diagnostic growth FY27-29 guides 40% margin within months.
  • Balance sheet stretched after receivables and inventory surge; government work collects in ~4 months; no Q1 cash update.
  • Pharmacy divestment completion effective 1 September 2026
    ₹16.77Cr proceeds for diagnostics; ~₹32Cr quarterly pharmacy revenue exits.
  • Jankipuram flagship centre September 2026 guided
    ₹32.82Cr Lucknow flagship comes online.
  • 40% diagnostic margin test next few months
    lifts reported margin toward 40% after pharmacy exit.
  • Owned-centre rollout before December 2026 guided
    8 comprehensive plus >6 lab/radiology centres open; ~₹10Cr plus capex.
  • >1,000-franchise rollout FY27
    collection network expands from 375 toward >1,000.
Price Range

See where the stock is trading versus its 52-week high and low.

Low
185
52W Range
High
358
Timeline

Key company specific updates.

Custom financial statement

Edit rows

Forensics

11 Yes

Positive for this company

3 Neutral

Neutral for this company

1 No

Negative for this company

2 No Data

Insufficient data to analyse

Revenue mix

Product Wise Break-Up

Peer Comparison

FAQs on Chandan Healthcare Ltd. Business

Chandan Healthcare specializes in operating state-of-the-art laboratories that offer comprehensive pathological investigations. Its services encompass biochemistry, hematology, histopathology, microbiology, and immunology. Additionally, it provides an extensive array of radiology services, including CT scans, X-rays, and MRIs.

Chandan Healthcare major competitors are Pramodini Medicare, Nephro Care India, Modern Diagnostic.
Market Cap of Chandan Healthcare is ₹497 Crs.
While the median market cap of its peers are ₹151 Crs.

Chandan Healthcare seems to be financially stable compared to its competitors.
The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.

Company Filing

2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
Annual Report FY26 FY25 FY24 FY23 FY22 FY21 FY20 FY19 FY18 FY17 FY16 FY15 FY14 FY13 FY12 FY11 FY10
Earnings Release
Investor Presentation
Conference Call
Conference Call SummaryCon Call Summary

Discussions & Analysis

Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material